Provided by Tiger Trade Technology Pte. Ltd.

PaxMedica, Inc.

0.0007
+0.000240.00%
Volume:3K
Turnover:2.15
Market Cap:88.20K
PE:0.00
High:0.0007
Open:0.0005
Low:0.0005
Close:0.0005
52wk High:0.0200
52wk Low:0.0000
Shares:126.00M
Float Shares:126.00M
Volume Ratio:5.49
T/O Rate:0.00%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9124
EPS(LYR):-10.9994
ROE:-7716.49%
ROA:-370.36%
PB:-0.05
PE(LYR):0.00

Loading ...

Company Profile

Company Name:
PaxMedica, Inc.
Exchange:
EXPERT
Establishment Date:
2018
Employees:
7
Office Location:
303 South Broadway,Suite 125,Tarrytown,New York,United States
Zip Code:
10591
Fax:
- -
Introduction:
PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms. The company's lead product candidate is PAX-101, an intravenous formulation of suramin for various indications, including autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, and human African trypanosomiasis (HAT). It also develops PAX-102, an intranasal formulation of suramin for neurologic indications; and HAT-301 for the treatment of stage 1 East African HAT. The company has a research collaboration with PoloMar Health to investigate the use of emodin in a clinical program as a potential treatment for patients with autism spectrum disorder The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York.